01779

116.7005.43%

Jul 13 at 05:09 AM

$ZAI LAB(09688.HK), $CSTONE PHARMA-B(02616.HK) have always had a seat at the table for out-licensing, while $TH MEDICAL-B(02697.HK), $LONGBIO-B(01779.HK), $JIANGXI BIO(06915.HK) — this batch of B-suffix companies are still grinding through clinical trials. As the story of innovative drugs unfolds this year, patience is more valuable than vision 🥲

TH MEDICAL-B

HK02697

LONGBIO-B

HK01779

JIANGXI BIO

HK06915

ZAI LAB

HK09688

CSTONE PHARMA-B

HK02616

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.